Patents by Inventor Man Lun Yip
Man Lun Yip has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210121427Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: October 19, 2020Publication date: April 29, 2021Inventors: JAMES TURKSON, SAID M. SEBTI, WAYNE GUIDA, MAN LUN YIP, NICHOLAS LAWRENCE, HARSHANI RITHMA LAWRENCE, BENJAMIN GREEDY
-
Patent number: 10806712Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: GrantFiled: March 11, 2019Date of Patent: October 20, 2020Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
-
Publication number: 20190192461Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: March 11, 2019Publication date: June 27, 2019Inventors: JAMES TURKSON, SAID M. SEBTI, WAYNE GUIDA, MAN LUN YIP, NICHOLAS LAWRENCE, HARSHANI RITHMA LAWRENCE, BENJAMIN GREEDY
-
Patent number: 10226439Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: GrantFiled: March 24, 2017Date of Patent: March 12, 2019Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
-
Patent number: 9951316Abstract: Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.Type: GrantFiled: January 7, 2015Date of Patent: April 24, 2018Assignee: City of HopeInventors: Yanhong Shi, Man Lun Yip, Wendong Li
-
Publication number: 20170202795Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: March 24, 2017Publication date: July 20, 2017Inventors: JAMES TURKSON, SAID M. SEBTI, WAYNE GUIDA, MAN LUN YIP, NICHOLAS LAWRENCE, HARSHANI RITHMA LAWRENCE, BENJAMIN GREEDY
-
Patent number: 9604923Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: GrantFiled: April 7, 2014Date of Patent: March 28, 2017Assignees: H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
-
Publication number: 20150191701Abstract: Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.Type: ApplicationFiled: January 7, 2015Publication date: July 9, 2015Inventors: Yanhong Shi, Man Lun Yip, Wendong Li
-
Patent number: 8962322Abstract: Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.Type: GrantFiled: October 15, 2013Date of Patent: February 24, 2015Assignee: City of HopeInventors: Yanhong Shi, Man Lun Yip, Wendong Li
-
Publication number: 20140329900Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: April 7, 2014Publication date: November 6, 2014Applicants: H. Lee Moffitt Cancer Center And Research Institute, Inc., University of Central Florida, University of South FloridaInventors: JAMES TURKSON, SAID M. SEBTI, WAYNE GUIDA, MAN LUN YIP, NICHOLAS LAWRENCE, HARSHANI RITHMA LAWRENCE, BENJAMIN GREEDY
-
Publication number: 20140154805Abstract: Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.Type: ApplicationFiled: October 15, 2013Publication date: June 5, 2014Applicant: City of HopeInventors: Yanhong Shi, Man Lun Yip, Wendong Li
-
Publication number: 20110201576Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: February 4, 2011Publication date: August 18, 2011Applicants: H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, University of Central FloridaInventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas J. Lawrence, Harshani Lawrence, Benjamin Greedy
-
Patent number: 7960434Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: GrantFiled: May 21, 2007Date of Patent: June 14, 2011Assignees: University of South Florida, University of Central Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center & Research InstituteInventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas J. Lawrence, Harshani Lawrence, Benjamin Greedy
-
Publication number: 20090069420Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: May 21, 2007Publication date: March 12, 2009Applicants: H. Lee Moffitt Cancer Center & Research Institute, University of South FloridaInventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas J. Lawrence, Harshani Lawrence, Benjamin Greedy